Sunday 11 October 2026 Export all MRK data to Excel Powerpack

Merck & Co., Inc.

MRK Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.

145.60 3.22 +2.26%
Market cap
$351.3B
P/E
116×
Fwd P/E
53.9×
Dividend yield
2.34%
F-score
4/9
Altman Z
3.77
Beneish M
−2.27
Dividend safety
74/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

11.09 14.46 33.88 102.80
P/S ratio
3.26 4.05 4.52 4.77
P/FCF ratio
16.05 21.31 21.07 19.76
P/Operating CF
26.77 92.18 75.90 59.11
P/B ratio
4.03 5.00 6.47 7.56
EV/Sales
3.60 4.55 5.14 5.43
EV/EBITDA
8.57 10.58 17.60 26.38
EV/FCF
17.71 23.91 23.97 22.49
Current Ratio
1.66 1.54 1.30 1.32
Net Debt/EBITDA
2.82 4.93 (24.26) 38.21
Debt/Equity
0.77 0.89 1.02 1.22
Earnings Yield
9.02% 6.92% 2.95% 0.97%
Free Cash Flow Yield
6.23% 4.69% 4.75% 5.06%
Free Cash Flow per Share
2.74 0.73 1.18 1.81
Book value per Share
20.80 21.05 18.58 17.00
Free Cash Flow
6,835.00 1,824.00 2,927.00 4,477.00
EV/EBIT
10.32 13.37 26.09 51.74
Other line items

Show all line items

Columns are period end dates